China Resources Shuanghe: China Resources Shuanghe\'s Announcement on Changing the Secretary of the Board
China Resources Shuanghe: Announcement of Resolutions of the Third Meeting of the 10th Board of Directors of China Resources Shuanghe
Announcement of Resolutions of the Third Meeting of the 10th Board of Directors of China Resources Shuanghe
Announcement of China Resources Shuanghe on changing the secretary of the board
Announcement of Resolutions of the Third Meeting of the 10th Board of Supervisors of China Resources Shuanghe
Notice to creditors of China Resources Shuanghe\'s Notice to Creditors on Repurchase and Cancellation of Certain Restricted Shares to Reduce Registered Capital
The “Articles of Association” of China Resources Shuanghe Company (revised at the 2nd meeting of the 10th board of directors on August 21, 2024, and reviewed and approved by the 5th Extraordinary General Meeting of Shareholders in 2024 on September 19, 2024)
Legal Opinion of Beijing Zhonglun Law Firm on the 5th Extraordinary General Meeting of Shareholders of China Resources Shuanghe in 2024
Announcement of Resolutions of the Fifth Shareholders\' Meeting of China Resources Shuanghe 2024
China Resources Shuanghe Investor Relations Activity Record Form (2024-002)
Announcement of China Resources Shuanghe on the approval notice for the listing application of valproic acid and sodium valproate from the holding subsidiary Hunan Xiangzhong Pharmaceutical Co., Ltd.
Documents of the 5th Extraordinary General Meeting of Shareholders of China Resources Shuanghe 2024
Announcement of China Resources Shuanghe on the consistent evaluation of the quality and efficacy of generic drugs for injection of omeprazole sodium by its wholly-owned subsidiary Shuanghe Pharmaceutical (Hainan) Co., Ltd.
Announcement of China Resources Shuanghe on the fact that the wholly-owned subsidiary China Resources Zizhu Pharmaceutical Co., Ltd. obtained a notice of approval for drug clinical trials by ZP036
Announcement of China Resources Shuanghe on Busuan Injection Passing the Consistent Evaluation of the Quality and Efficacy of Generic Drugs
Notice of China Resources Shuanghe on Convening the Fifth Extraordinary General Meeting of Shareholders in 2024
Minutes of China Resources Shuanghe 2024 Interim Results Briefing
China Resources Double-Crane Pharmaceutical Announcement on the Main Business Data for the First Half of 2024
China Resources Double-Crane Pharmaceutical Announcement on the Resolution of the Second Meeting of the Tenth Supervisory Board
Legal Opinion of Beijing Zhonglun Law Firm on the Partial Cancellation of Restricted Stock Repurchase of China Resources Double-Crane Pharmaceutical Co., Ltd.'s 2021 Restricted Stock Incentive Plan
No Data
No Data